A plain-language guide

catecholaminergic polymorphic ventricular tachycardia

What's known, what's still uncertain, and what's actively debated, written plainly, and built only from published medical research.

Early map · 16 sourced statements Every statement names its source Updated 2026-08-04
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. catecholaminergic polymorphic ventricular tachycardia is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's catecholaminergic polymorphic ventricular tachycardia?

Catecholaminergic polymorphic ventricular tachycardia is a rare but potentially lethal inherited arrhythmia syndrome, characterized by bidirectional or polymorphic ventricular tachycardia provoked by exercise or emotion.

Also indexed asORPHA:3286, MONDO:0017990
Features mapped9
Treatments mapped2
Published sources9
Last reviewed2026-08-04

Signs and symptoms

Sudden cardiac death

Sudden cardiac death remains a risk in this condition even for people already on medical therapy. That residual risk is why treatment is often intensified beyond a single drug.

Limited evidenceSource: PMID:38588993
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:3286, PMID:33763313
Notesplain_language confirmed from PMID:33763313 via curation 2026-07-29 [llm:claude-fable-5]. | regrounded primary ORPHA:3286 -> PMID:33763313 on 2026-07-29 [Carrie Schluter, BCPA] | regrounded primary PMID:33763313 -> PMID:38588993 on 2026-07-30 [Carrie Schluter, BCPA]
Last reviewed2026-07-30

Cardiac arrest

The heart can stop pumping without warning. Illness is most severe in younger people, who typically first come to attention with cardiac arrest or with fainting caused by an abnormal rhythm.

Limited evidenceSource: PMID:34502196
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:3286
Notesplain_language confirmed from PMID:34502196 via curation 2026-07-29 [llm:claude-fable-5]. | regrounded primary ORPHA:3286 -> PMID:34502196 on 2026-07-29 [Carrie Schluter, BCPA]
Last reviewed2026-07-29

Polymorphic ventricular tachycardia

Polymorphic ventricular tachycardia is a fast, unstable rhythm of the heart's main pumping chambers in which each beat takes a different shape. In this condition it is brought on by exercise or by strong emotion.

Limited evidenceSource: PMID:34502196
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:3286
Notesplain_language confirmed from PMID:34502196 via curation 2026-07-29 [llm:claude-fable-5]. | regrounded primary ORPHA:3286 -> PMID:34502196 on 2026-07-29 [Carrie Schluter, BCPA]
Last reviewed2026-07-29

Supraventricular tachycardia

Fast rhythms starting in the heart's upper chambers also occur. In a cohort of 206 people with this condition, 17, or 8.3 percent, had one, including atrial fibrillation, atrial flutter, atrial tachycardia and supraventricular tachycardia.

Limited evidenceSource: PMID:39918456
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:3286
Notesplain_language confirmed from PMID:39918456 via curation 2026-07-29 [llm:claude-fable-5]. | regrounded primary ORPHA:3286 -> PMID:39918456 on 2026-07-29 [Carrie Schluter, BCPA]
Last reviewed2026-07-29

Syncope

Fainting after exercise or after becoming upset is the way this condition most often announces itself. Fainting and sudden death following exertion or agitation are the main clinical signs.

Limited evidenceSource: PMID:34483927
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:3286
Notesplain_language confirmed from PMID:34483927 via curation 2026-07-29 [llm:claude-fable-5]. | regrounded primary ORPHA:3286 -> PMID:34483927 on 2026-07-29 [Carrie Schluter, BCPA]
Last reviewed2026-07-29

Bidirectional ventricular tachycardia

Bidirectional ventricular tachycardia is a fast rhythm in which beats alternate direction from one to the next. It is the signature tracing of this condition, and it appears when exercise or emotion raises adrenaline. It can lead to repeated fainting and to sudden death.

Limited evidenceSource: PMID:41306755
Evidence ratingweak
Study designliterature_review
Confidence (0-1)0.7
Replicationunreplicated
Notesplain_language confirmed from PMID:41306755 via curation 2026-07-29 [llm:claude-fable-5].
Last reviewed2026-07-29

Structurally normal heart

The heart itself is built normally. Imaging shows no damage or malformation; the problem is electrical, and the abnormal rhythms are driven by adrenaline.

Limited evidenceSource: PMID:41306755
Evidence ratingweak
Study designliterature_review
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42292508
Notesplain_language confirmed from PMID:42292508 via curation 2026-07-29 [llm:claude-fable-5].
Last reviewed2026-07-29

Unremarkable resting electrocardiogram

A resting electrocardiogram is usually normal, and so is a Holter monitor. The abnormal rhythm shows up only when the heart is stressed, which is why exercise stress testing is what reveals bidirectional ventricular tachycardia.

Limited evidenceSource: PMID:41306755
Evidence ratingweak
Study designliterature_review
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42435031
Notesplain_language confirmed from PMID:42435031 via curation 2026-07-29 [llm:claude-fable-5].
Last reviewed2026-07-29

Onset in childhood

Symptoms usually begin in childhood. The median age at which the condition first declares itself is about ten years.

Limited evidenceSource: PMID:41306755
Evidence ratingweak
Study designliterature_review
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:34502196
Notesplain_language confirmed from PMID:34502196 via curation 2026-07-29 [llm:claude-fable-5].
Last reviewed2026-07-29

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

flecainide

Flecainide is added to beta-blocker treatment. Adding it raises the share of people whose arrhythmia is controlled from 60 to 70 percent on a beta-blocker alone to 80 to 90 percent, and it works by acting directly on the RyR2 calcium-release channel.

Used to help with: Catecholaminergic polymorphic ventricular tachycardia.

Limited evidenceSource: PMID:42378424
The source text this rests on
“…the addition of flecainide to beta-blocker therapy was associated with a significant reduction in arrhythmic burden and improvement in exercise-related parameters during long-term…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41694040
Notesconfirmed from PMID:42378424 via curation 2026-07-29
Last reviewed2026-07-29

left cardiac sympathetic denervation

Left cardiac sympathetic denervation is surgery that interrupts the nerves carrying adrenaline signals to the heart. Combined with a beta-blocker and flecainide it significantly reduced breakthrough cardiac events, though it did not prevent aborted cardiac arrest or sudden death.

Used to help with: Catecholaminergic polymorphic ventricular tachycardia.

Limited evidenceSource: PMID:40784471
The source text this rests on
“Triple therapy with beta-blockers, flecainide, and LCSD significantly reduced BCEs (p = 0.044), but not ACA/SCD (p =…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40784471 via curation 2026-07-29
Last reviewed2026-07-29

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.
No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 9 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

PMID:34483927 · Advances in the Molecular Genetics of Catecholaminergic Polymorphic Ventricular Tachycardia.
PMID:34502196 · Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: A Translational Perspective for the Clinician-Scientist.
PMID:38588993 · An international multicenter cohort study on implantable cardioverter-defibrillators for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia.
PMID:39918456 · Incidence and Clinical Management of Supraventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
PMID:40784471 · Arrhythmic Risk and Clinical Features in Catecholaminergic Polymorphic Ventricular Tachycardia: Results From a Multicent
PMID:40875405 · RYR2 Variants in Catecholaminergic Polymorphic Ventricular Tachycardia Patients: Insights From Protein Structure and Clinical Data.
PMID:41306755 · CPVT cardinal clinical features absent from the HPO scaffold (literature)
PMID:41694040 · Ryanodine receptor 2 mutations in catecholaminergic polymorphic ventricular tachycardia: From molecular mechanisms to pr
PMID:42378424 · Long-Term Serial Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia on Beta-Blocker and Fl

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.